Mirataz is the first FDA approved transdermal ointment to manage weight loss in cats due to underlying diseases such as hyperthyroidism, chronic kidney disease, inflammatory bowel disease, neoplasia, pancreatitis, and liver failure.  Mirataz is a serotonin and histamine receptor antagonist that has demonstrated to increase body weight in cats that are experiencing unintended weight loss, it has been classified as a weight gain drug.

• Only FDA approved transdermal medication for the management of weight loss in cats.
• Give you a practical way to manage your cat's weight loss without having to administer oral medication and does not rely on your cat to eat to be medicated.
• Can result in significant weight gain in cats in as little as 14 days.
• Due to proprietary Accusorb technology, Mirataz achieves measurable plasma concentrations of mirtazapine in cats.
• Clinical studies showed Mirataz was well tolerated both locally and systemically

The most common side effects have been application-site reactions, increased vocalization, hyperactivity, and vomiting.  If these symptoms persist, contact your veterinarian. Notify your veterinarian if symptoms are troublesome and continue.  Other side effects may occur.  If you notice anything unusual, contact your veterinarian.

Wear gloves when handling & applying, wash hands after use. Apply as directed by your veterinarian to the inside of your cats ear once daily. Avoid contact between the treated cat and people or other animals for 2 hours after application.

Mirataz is for use under veterinary supervision only. Do not use in cats with a known hypersensitivity to mirtazapine or any of the exipients.  Do not use in cats treated with monoamine oxidase inhibitors. Not for human use.  Keep out of reach of children. Wear gloves when handling/applying and wash hands after use. Use with caution in cats with hepatice and kidney disease. Safety has not been evaluated in cats less than 2 kg, less than 6 months of age, or in breeding, pregnant, or lactating cats. Food intake should be monitored upon discontinuation of medication.